Literature DB >> 22052465

Autocrine CSF-1 and CSF-1 receptor coexpression promotes renal cell carcinoma growth.

Julia Menke1, Jörg Kriegsmann, Carl Christoph Schimanski, Melvin M Schwartz, Andreas Schwarting, Vicki R Kelley.   

Abstract

Renal cell carcinoma is increasing in incidence but the molecular mechanisms regulating its growth remain elusive. Coexpression of the monocytic growth factor colony-stimulating factor (CSF)-1 and its receptor CSF-1R on renal tubular epithelial cells (TEC) will promote proliferation and antiapoptosis during regeneration of renal tubules. Here, we show that a CSF-1-dependent autocrine pathway is also responsible for the growth of renal cell carcinoma (RCC). CSF-1 and CSF-1R were coexpressed in RCCs and TECs proximally adjacent to RCCs. CSF-1 engagement of CSF-1R promoted RCC survival and proliferation and reduced apoptosis, in support of the likelihood that CSF-1R effector signals mediate RCC growth. In vivo CSF-1R blockade using a CSF-1R tyrosine kinase inhibitor decreased RCC proliferation and macrophage infiltration in a manner associated with a dramatic reduction in tumor mass. Further mechanistic investigations linked CSF-1 and epidermal growth factor signaling in RCCs. Taken together, our results suggest that budding RCC stimulates the proximal adjacent microenvironment in the kidney to release mediators of CSF-1, CSF-1R, and epidermal growth factor expression in RCCs. Furthermore, our findings imply that targeting CSF-1/CSF-1R signaling may be therapeutically effective in RCCs. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22052465      PMCID: PMC3251714          DOI: 10.1158/0008-5472.CAN-11-1232

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

1.  Expression of acute and late-stage inflammatory antigens, c-fms, CSF-1, and human monocytic serine esterase 1, in tumor-associated macrophages of renal cell carcinomas.

Authors:  B Hemmerlein; A Markus; M Wehner; A Kugler; F Zschunke; H J Radzum
Journal:  Cancer Immunol Immunother       Date:  2000-11       Impact factor: 6.968

2.  Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression.

Authors:  Hisamitsu Ide; David B Seligson; Sanaz Memarzadeh; Li Xin; Steve Horvath; Purnima Dubey; Maryann B Flick; Barry M Kacinski; Aarno Palotie; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-15       Impact factor: 11.205

Review 3.  The EGF receptor family as targets for cancer therapy.

Authors:  J Mendelsohn; J Baselga
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

4.  Adenosine attenuates oxidant injury in human proximal tubular cells via A(1) and A(2a) adenosine receptors.

Authors:  H T Lee; Charles W Emala
Journal:  Am J Physiol Renal Physiol       Date:  2002-05

5.  Control of the epidermal growth factor receptor and its ligands during renal injury.

Authors:  M K Hise; M Salmanullah; L Liu; C I Drachenberg; J C Papadimitriou; R M Rohan
Journal:  Nephron       Date:  2001-05       Impact factor: 2.847

6.  Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice.

Authors:  Seyedhossein Aharinejad; Dietmar Abraham; Patrick Paulus; Hojatollah Abri; Michael Hofmann; Karl Grossschmidt; Romana Schäfer; E Richard Stanley; Reinhold Hofbauer
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

7.  IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology.

Authors:  Eriya Kikawada; Deborah M Lenda; Vicki R Kelley
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

8.  Overexpression of the colony-stimulating factor (CSF-1) and/or its receptor c-fms in mammary glands of transgenic mice results in hyperplasia and tumor formation.

Authors:  Nameer Kirma; Roopa Luthra; Jeremy Jones; Ya-Guang Liu; Hareesh B Nair; Usha Mandava; Rajeshwar Rao Tekmal
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

9.  Importance of functional EGF receptors in recovery from acute nephrotoxic injury.

Authors:  Zoufei Wang; Jian-Kang Chen; Su-Wan Wang; Gilbert Moeckel; Raymond C Harris
Journal:  J Am Soc Nephrol       Date:  2003-12       Impact factor: 10.121

10.  CSF-1 signals directly to renal tubular epithelial cells to mediate repair in mice.

Authors:  Julia Menke; Yasunori Iwata; Whitney A Rabacal; Ranu Basu; Yee G Yeung; Benjamin D Humphreys; Takashi Wada; Andreas Schwarting; E Richard Stanley; Vicki R Kelley
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

View more
  23 in total

1.  IL-34-Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL-Faslpr Mice.

Authors:  Yukihiro Wada; Hilda M Gonzalez-Sanchez; Julia Weinmann-Menke; Yasunori Iwata; Amrendra K Ajay; Myriam Meineck; Vicki R Kelley
Journal:  J Am Soc Nephrol       Date:  2019-01-08       Impact factor: 10.121

Review 2.  Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?

Authors:  Axel Bex; Tamara Etto; Florry Vyth-Dreese; Christian Blank; Arjan W Griffioen
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

Review 3.  Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases.

Authors:  Kenneth Verstraete; Savvas N Savvides
Journal:  Nat Rev Cancer       Date:  2012-10-18       Impact factor: 60.716

Review 4.  Tumour and patient factors in renal cell carcinoma-towards personalized therapy.

Authors:  Ahmed Q Haddad; Vitaly Margulis
Journal:  Nat Rev Urol       Date:  2015-04-14       Impact factor: 14.432

Review 5.  Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics.

Authors:  James H Finke; Pat A Rayman; Jennifer S Ko; Judy M Bradley; Sandra J Gendler; Peter A Cohen
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

6.  Macrophage density and macrophage colony-stimulating factor expression predict the postoperative prognosis in patients with intrahepatic cholangiocarcinoma.

Authors:  Kosuke Oishi; Takanori Sakaguchi; Satoshi Baba; Shohachi Suzuki; Hiroyuki Konno
Journal:  Surg Today       Date:  2014-07-23       Impact factor: 2.549

7.  Glioblastoma-derived Macrophage Colony-stimulating Factor (MCSF) Induces Microglial Release of Insulin-like Growth Factor-binding Protein 1 (IGFBP1) to Promote Angiogenesis.

Authors:  Mamatha Bangalore Nijaguna; Vikas Patil; Serge Urbach; Shivayogi D Shwetha; Kotha Sravani; Alangar S Hegde; Bangalore A Chandramouli; Arimappamagan Arivazhagan; Philippe Marin; Vani Santosh; Kumaravel Somasundaram
Journal:  J Biol Chem       Date:  2015-08-05       Impact factor: 5.157

8.  The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.

Authors:  Orsi Giricz; Yongkai Mo; Kimberly B Dahlman; Xiomaris M Cotto-Rios; Chiara Vardabasso; Hoa Nguyen; Bernice Matusow; Matthias Bartenstein; Veronika Polishchuk; Douglas B Johnson; Tushar D Bhagat; Rafe Shellooe; Elizabeth Burton; James Tsai; Chao Zhang; Gaston Habets; John M Greally; Yiting Yu; Paraic A Kenny; Gregg B Fields; Kith Pradhan; E Richard Stanley; Emily Bernstein; Gideon Bollag; Evripidis Gavathiotis; Brian L West; Jeffrey A Sosman; Amit K Verma
Journal:  JCI Insight       Date:  2018-07-26

9.  Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma.

Authors:  Liu Yang; Qian Wu; Le Xu; Weijuan Zhang; Yu Zhu; Haiou Liu; Jiejie Xu; Jianxin Gu
Journal:  BMC Cancer       Date:  2015-02-18       Impact factor: 4.430

10.  Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.

Authors:  Eva Juengel; Dana Kim; Jasmina Makarević; Michael Reiter; Igor Tsaur; Georg Bartsch; Axel Haferkamp; Roman A Blaheta
Journal:  J Cell Mol Med       Date:  2014-12-02       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.